Related Experiment Video

Updated: Sep 6, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

[Resistance to BRAF inhibitors: A lesson from clinical observations]

Cylia Dahmani1, Eulalie Corre2, Sarah Dandou3

  • 1IBMM, université de Montpellier, CNRS, ENSCM, Montpellier, France - Groupe de la chaire de recherche du Canada en pharmacogénomique, Faculté de pharmacie de l'université Laval, Centre de recherche du CHU de Québec - université Laval (CRCHUQc-UL), Québec, QC, Canada.

Medecine Sciences : M/S
|June 29, 2022
PubMed

Insights

BRAF inhibitors target the MAPK/ERK pathway in cancer, but resistance limits their effectiveness. This review explores BRAF inhibitor development and resistance mechanisms to improve cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • The MAPK/ERK pathway is crucial for cell signaling and its dysregulation contributes to cancer.
  • Activating BRAF mutations are common in various cancers, leading to targeted therapy development.
  • BRAF inhibitors offer therapeutic potential but face challenges with primary and acquired resistance.

Purpose of the Study:

  • To review the development of BRAF inhibitors.
  • To detail the molecular and cellular mechanisms of resistance to BRAF inhibitors in cancer.
  • To highlight the importance of understanding resistance for future therapeutic strategies.

Main Methods:

  • Literature review of BRAF inhibitor development.
  • Analysis of molecular mechanisms underlying BRAF inhibitor resistance.
  • Examination of cellular mechanisms of resistance in cancer.

Main Results:

  • BRAF inhibitors have shown promise but exhibit variable efficacy due to resistance.
  • Primary resistance limits initial treatment effectiveness.
  • Acquired resistance leads to treatment failure over time.

Conclusions:

  • Understanding BRAF inhibitor resistance mechanisms is critical for improving cancer treatment outcomes.
  • Further research into overcoming resistance is essential for developing more effective BRAF-targeted therapies.
  • This review provides insights into resistance pathways to guide future drug development.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K